| Title |
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, June 2013
|
| DOI | 10.2147/ndt.s45144 |
| Pubmed ID | |
| Authors |
Alessandra Lugaresi, Maria di Ioia, Daniela Travaglini, Erika Pietrolongo, Eugenio Pucci, Marco Onofrj |
| Abstract |
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and mainly affects young adults. Its natural history has changed in recent years with the advent of disease-modifying drugs, which have been available since the early 1990s. The increasing number of first-line and second-line treatment options, together with the variable course of the disease and patient lifestyles and expectations, makes the therapeutic decision a real challenge. The aim of this review is to give a comprehensive overview of the main present and some future drugs for relapsing-remitting MS, including risk-benefit considerations, to enable readers to draw their own conclusions regarding the risk-benefit assessment of personalized treatment strategies, taking into account not only treatment-related but also disease-related risks. We performed a Medline literature search to identify studies on the treatment of MS with risk stratification and risk-benefit considerations. We focused our attention on studies of disease-modifying, immunomodulating, and immunosuppressive drugs, including monoclonal antibodies. Here we offer personal considerations, stemming from long-term experience in the treatment of MS and thorough discussions with other neurologists closely involved in the care of patients with the disease. MS specialists need to know not only the specific risks and benefits of single drugs, but also about drug interactions, either in simultaneous or serial combination therapy, and patient comorbidities, preferences, and fears. This has to be put into perspective, considering also the risks of untreated disease in patients with different clinical and radiological characteristics. There is no single best treatment strategy, but therapy has to be tailored to the patient. This is a time-consuming task, rich in complexity, and influenced by the attitude towards risk on the parts of both the patient and the clinical team. The broader the MS drug market becomes, the harder it will be for the clinician to help the patient decide which therapeutic strategy to opt for. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 136 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 14% |
| Student > Master | 19 | 14% |
| Student > Bachelor | 19 | 14% |
| Other | 15 | 11% |
| Researcher | 13 | 9% |
| Other | 27 | 20% |
| Unknown | 26 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 35% |
| Nursing and Health Professions | 8 | 6% |
| Agricultural and Biological Sciences | 7 | 5% |
| Psychology | 7 | 5% |
| Neuroscience | 6 | 4% |
| Other | 25 | 18% |
| Unknown | 37 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2022.
All research outputs
#7,205,295
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#913
of 3,132 outputs
Outputs of similar age
#57,744
of 206,480 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#9
of 54 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,480 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.